Citable filing context

JNJ filing events and research context

Server-rendered

JNJ's research view summarizes recent SEC filing context, starting with earnings from Jan 21, 2026.

JNJ filing events and research context
FiledItemContext
Jan 21, 2026earningsJohnson & Johnson released its financial results.
Oct 14, 2025debt_offeringJohnson & Johnson registered various debt notes, including 1.150% Notes Due November 2028.
Sep 9, 2025management_changeChanges in directors or officers and their compensatory arrangements.
Apr 14, 2026Guidance: adjusted_eps_diluted11.45 to 11.65
Apr 14, 2026Guidance: adjusted_eps_diluted_growth6.10 to 8.10
Apr 14, 2026Guidance: adjusted_operational_eps_diluted11.30 to 11.50
Apr 22, 2026mda_quarterlyJohnson & Johnson repurchased an aggregate of 16,834,220 shares of its common stock during the fiscal first quarter of 2026, spanning from December 29, 2025, to March 29, 2026. These shares were acquired through open-market transactions at an average price of $239.26 per share. The repurchases were conducted as part of a systematic plan to fulfill the Company’s compensation program requirements, and this total included shares from stock-for-stock option exercises settled within the quarter. No shares were purchased under any publicly announced repurchase plans or programs, and no remaining authorization existed under such programs.
Feb 11, 2026businessJohnson & Johnson operates globally through a diverse portfolio of pharmaceutical and medical technology businesses, as evidenced by its extensive list of U.S. and international subsidiaries. Key areas include pharmaceuticals (e.g., Janssen Biotech, Actelion Pharmaceuticals), medical devices (e.g., Ethicon, DePuy Orthopaedics, Biosense Webster, ABIOMED for cardiovascular support, Shockwave Medical), and

Source: SEC EDGAR filing text and events; period Jan 21, 2026; filed Jan 21, 2026.

Continue research

Keep researching JNJ

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →
AMGN
AMGEN INC
$186.59B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →